Table 1.

BIRC3 and BIRC5 roles in different cancers

Tumor type	Function	References
BIRC3
Oral squamous cell carcinoma (OSCC)	Pro-oncogenic: poor prognosis, metastasis, radioresistance	[7, 8]
Chronic lymphocytic leukemia (CLL)	Oncosuppressive: disruptions predict poor prognosis, inferior outcome, chemoresistance. Neg. regulator of the non-canonical NF-kB pathw.	[36–45, 49]
Chronic lymphocytic leukemia (CLL)	Pro-oncogenic: higher expression in leukemia cells, downregulated by SMAC-mimetics	[50]
Mantle-cell lymphoma (MCL)	Oncosuppressive: mutations activate the non-canonical NF-kB pathw.	[51–54]
Glioma, glioblastoma (GBM)	Pro-oncogenic: gene expression inversely correlates to survival and therapy resistance. Higher expression in HGG	[3, 12, 56]
Breast cancer	Pro-oncogenic: antiapoptotic, chemoresistance	[57–62]
Breast cancer	Oncosuppressive: high expression correlates to drug sensitivity	[2]
BIRC5
Lung, pancreatic, breast, ovarian, brain, colon cancer	Pro-oncogenic	[63–65]
B-cell acute lymphoblastic leukemia, B-cell lymphoma and T-cell leukemia/lymphoma	Pro-oncogenic	[66–68]
Hepatocellular carcinoma (HCC)	Pro-oncogenic: high expression correlates to lower survival	[70]
Gastrointestinal stromal tumors (GIST)	Pro-oncogenic: high expression correlates to lower survival	[71]
Prostate cancer	Pro-oncogenic: high expression correlates to p53 mutations and metastases. Cytoplasmic localization associates to an aggressive disease	[72, 74]
Gioma, astrocytoma, glioblastoma, medulloblastoma	Pro-oncogenic: anti-apoptotic function. High expression correlates to lower short-term and long-term survival. Overexpression increases chromosomal aberrations	[64, 75–79]
Colorectal cancer, ALL, melanoma, glioblastoma	Pro-oncogenic: silencing and inhibition leads to chemo- and radiosensitization	[80–84]